EDP-323, an investigational inhibitor of Respiratory Syncytial Virus (RSV), is showing promising results in Phase 2a trials. While other RSV therapies and vaccines are approved for prevention, EDP-323 ...
BOTHELL, Wash., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel small molecule ...
Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 Cocrystal Pharma’s pan-viral ...
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the ...
Please provide your email address to receive an email when new articles are posted on . Influenza vaccines, masking and other infection prevention methods are effective control measures. Still, ...
This new article publication from Acta Pharmaceutica Sinica B, discusses the identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics. There are only eight approved small ...
This new article publication from Acta Pharmaceutica Sinica B, discusses the discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model ...
Transarterial chemoembolization plus donafenib and immune checkpoint inhibitors for intermediate hepatocellular carcinoma (CHANCE2410): A propensity score matching analysis. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results